MAXHEALTH Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,068 Cr
verified against source
Revenue YoY
10%
reported change
EBITDA
₹648 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Max Healthcare delivered its 21st consecutive quarter of YoY growth with Q3 FY26 revenue of ₹2,608 crore (+10% YoY), though EBITDA grew only 4% to ₹648 crore with margin compression of 120bps to 26.1%. The underperformance versus historical trends was attributed to: (1) cashless insurance service disruption with four insurers that has now been fully restored with an automatic annual increment mechanism; (2) CGHS pricing revisions on patented chemotherapy drugs resulting in discontinuation of low-margin drugs; (3) GST rate changes impacting both revenue and margins; and (4) pre-commissioning expenses for brownfield beds at Nanavati and Saket. Management expects a sequential recovery from Q4 with full CGHS tariff revision impact kicking in from April 2026. The network commissioned 116 brownfield beds (63 at Nanavati, 53 at Saket) with 91 currently occupied, all margin-accretive. The board approved an additional 260 beds at Max Dwarka (already at ~80% occupancy with 20% margins) taking total to 560 beds. Net debt stands at ₹2,166 crore with net debt/EBITDA below 1x. Key expansion projects remain on track: Max Shalimar (200 beds) awaiting occupancy certificate by February-end; Gurgaon (500 beds) expected H1 FY27. Looking ahead 2-3 years, operational beds should reach 6,000-6,500 by FY28. Risk: potential insurance pricing pressure from other insurers and uncertainty around CGHS oncology drug pricing negotiations.
Colored figures show movement against the previous available record.
Guidance to track
- Network operational beds currently ~4,600 expected to grow to 6,000-6,500 by FY28 through brownfield and greenfield projects including new hospitals in Pune (450 beds), Dehradun (100 beds), and expanded facilities at existing locations.
- Net positive impact of approximately ₹200 crore annually from CGHS/ECHS tariff revisions, partially offset by ₹80 crore from discontinued oncology drugs and ₹60 crore from GST changes, resulting in ₹140 crore net sustained impact. Full effect expected from Q1 FY27.
- 200-bed facility at Max Shalimar with operation theaters and OPDs ready, awaiting occupancy certificate expected by end of February 2026.
- 500-bed hospital at Sector 56, Gurgaon expected to commission first phase by end of H1 FY27, with pace of construction normalized post-monsoon disruptions.
Risks flagged
- CGHS wants 30% discount on patented chemotherapy drugs versus MRP, while Max's margins on these drugs are less than 20%, making supply uneconomical. Discussions ongoing for cost-plus arrangement. Management views this as temporary adjustment affecting ~80 crore annual revenue.
- Analyst specifically asked about expected losses from Gurgaon greenfield hospital. Management declined to provide guidance, stating it depends on clinician recruitment timing. Historical greenfield losses at Dehradun totaled ~30 crore to break-even in 6 months.
- Management acknowledged lessons learned from four insurer disputes but did not confirm whether similar disputes could occur with other insurance companies. The mechanism for annual automatic renewal was only established with those four companies.
- Management noted Q3 was severely impacted by lack of vector-borne diseases due to extended monsoon into winter. While Q4 typically benefits from flu season, this remains a recurring demand volatility factor beyond management control.
Key quotes
- We are pleased to share that the network delivered its 21st consecutive quarter of year-on-year growth in quarter 3 despite excessive unanticipated seasonal softness due to lack of vector-borne diseases and transitionary external factors.
- I think the big deterrent on our growth has been capacity. Essentially if I go beyond the seasonality of it and whatever one-time disruptions which are back to normal, everything that we've acquired or the new capacity that we set up have been ramping up very well.
- Annualized EBITDA per bed for the network stood at ₹71 lakhs versus ₹73 lakhs in both Q3 FY25 and the previous quarter. The two big factors affecting profitability were seasonality and the insurance disruption where we replaced all of that with institutional business, so occupancy didn't get impacted but quality of revenues got impacted.
Research modules